| 1. |
CR oxycodone cost study biased? |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 460,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
QOL improves following superior lumiracoxib effect in OA |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 460,
2004,
Page 3-4
L Everitt,
Preview
|
|
摘要:
Osteoarthritis (OA) is a highly prevalent, chronic disease affecting the joints. Stiffness and pain associated with this condition contributes to patients' inability to perform normal activities on a daily basis. Lumiracoxib [Prexige] is a selective and highly potent inhibitor of cyclo-oxygenase (COX)-2 in development by Novartis for the treatment of OA, acute pain and rheumatoid arthritis. At the Annual European Congress of Rheumatology (EULAR) [Berlin, Germany; June2004], a multinational investigative team presented the results of its multicentre, randomised trial in patients with primary OA, and revealed that lumiracoxib brought about"clinically relevant improvements in the patient's condition".1The results of a second randomised trial presented at the meeting showed that all aspects of QOL improved significantly following treatment with lumiracoxib, compared with placebo.2
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Cost, not adherence, main barrier to antiretroviral treatment in Africa |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 460,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Spironolactone: extrapolation of trial results inappropriate? |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 460,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Bupropion prescribing cautious in Ireland |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 460,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Ibutilide plus magnesium cost effective for AF |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 460,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Testing for coeliac disease in suspected IBS warranted? |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 460,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
The overall medical and mental health costs associated with eating disorders cost US businesses > $US3.8 billion in 2001, |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 460,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
HRQOL predictive of survival in breast cancer treatment |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 460,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
The new, fixed-dose combination antiretroviral emtricitabine/tenofovir disoproxil fumarate [Truvada] will be made available at not-for-profit prices in developing countries and in the US. |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 460,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
